Standout Papers

PD-1 and Its Ligands in Tolerance and Immunity 2005 2026 2012 2019 4.1k
  1. PD-1 and Its Ligands in Tolerance and Immunity (2008)
    Mary Keir, Manish J. Butte et al. Annual Review of Immunology
  2. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response (2018)
    Peng Jiang, Shengqing Gu et al. Nature Medicine
  3. Restoring function in exhausted CD8 T cells during chronic viral infection (2005)
    Daniel L. Barber, E. John Wherry et al. Nature
  4. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (2014)
    Stephen M. Ansell, Alexander M. Lesokhin et al. New England Journal of Medicine
  5. THE B7 FAMILY REVISITED (2005)
    Rebecca J. Greenwald, Gordon J. Freeman et al. Annual Review of Immunology
  6. CTLA-4 can function as a negative regulator of T cell activation (1994)
    Theresa L. Walunas, Deborah J. Lenschow et al. Immunity
  7. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (2009)
    Loise M. Francisco, Victor H. Salinas et al. The Journal of Experimental Medicine
  8. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection (2008)
    Shawn D. Blackburn, Haina Shin et al. Nature Immunology
  9. CD4+CD25high Regulatory Cells in Human Peripheral Blood (2001)
    Clare Baecher‐Allan, Julia A. Brown et al. The Journal of Immunology
  10. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses (2007)
    Manish J. Butte, Mary Keir et al. Immunity
  11. The B7–CD28 superfamily (2002)
    Arlene H. Sharpe, Gordon J. Freeman Nature reviews. Immunology
  12. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease (2002)
    Laurent Monney, Catherine A. Sabatos et al. Nature
  13. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy (2016)
    Se Jin Im, Masao Hashimoto et al. Nature
  14. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (2007)
    Arlene H. Sharpe, E. John Wherry et al. Nature Immunology
  15. Combination cancer immunotherapy and new immunomodulatory targets (2015)
    Kathleen M. Mahoney, Paul D. Rennert et al. Nature Reviews Drug Discovery
  16. Tissue expression of PD-L1 mediates peripheral T cell tolerance (2006)
    Mary Keir, Spencer C. Liang et al. The Journal of Experimental Medicine
  17. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation (2015)
    Nikolaos Patsoukis, Kankana Bardhan et al. Nature Communications
  18. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production (2003)
    Julia A. Brown, David M. Dorfman et al. The Journal of Immunology
  19. Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation (1993)
    Gordon J. Freeman, John G. Gribben et al. Science
  20. Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance (2017)
    Jinfang Zhang, Xia Bu et al. Nature
  21. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent (2017)
    Alice O. Kamphorst, Andreas Wieland et al. Science
  22. Coinhibitory Pathways in Immunotherapy for Cancer (2016)
    Susanne H.C. Baumeister, Gordon J. Freeman et al. Annual Review of Immunology
  23. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies (2013)
    Benjamin J. Chen, Bjoern Chapuy et al. Clinical Cancer Research
  24. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection (2010)
    Ana C. Anderson, Wendy G. Tan et al. Proceedings of the National Academy of Sciences
  25. Antigen-specific regulatory T cells develop via the ICOS–ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity (2002)
    Omid Akbari, Gordon J. Freeman et al. Nature Medicine
  26. Enhancing SIV-specific immunity in vivo by PD-1 blockade (2008)
    Vijayakumar Velu, Kehmia Titanji et al. Nature
  27. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity (2017)
    Vikram R. Juneja, Kathleen A. McGuire et al. The Journal of Experimental Medicine
  28. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome (2016)
    Margaretha G.M. Roemer, Ranjana H. Advani et al. Journal of Clinical Oncology
  29. Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma (1991)
    John G. Gribben, Arnold S. Freedman et al. New England Journal of Medicine
  30. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2 (2002)
    Laura Carter, Lynette A. Fouser et al. European Journal of Immunology
  31. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance (2003)
    Catherine A. Sabatos, Sumone Chakravarti et al. Nature Immunology
  32. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells (2004)
    Yvette Latchman, Spencer C. Liang et al. Proceedings of the National Academy of Sciences
  33. Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses (2003)
    Spencer C. Liang, Yvette Latchman et al. European Journal of Immunology
  34. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity (2010)
    Gordon J. Freeman, José M. Casasnovas et al. Immunological Reviews
  35. TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells (2007)
    Norimoto Kobayashi, Piia Karisola et al. Immunity
  36. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4 (1995)
    Gordon J. Freeman, Vassiliki A. Boussiotis et al. Immunity
  37. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy (2017)
    Sean P. Arlauckas, Christopher Garris et al. Science Translational Medicine
  38. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy (2017)
    Ying Zhang, Raj K. Kurupati et al. Cancer Cell
  39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma (2015)
    Kathleen M. Mahoney, Gordon J. Freeman et al. Clinical Therapeutics
  40. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade (2018)
    Wanqiang Sheng, Martin W. LaFleur et al. Cell
  41. The importance of exosomal PDL1 in tumour immune evasion (2020)
    Dhouha Daassi, Kathleen M. Mahoney et al. Nature reviews. Immunology
  42. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family (2016)
    Frank A. Schildberg, Sarah R. Klein et al. Immunity
  43. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy (2019)
    Melvyn T. Chow, Aleksandra J. Ozga et al. Immunity
  44. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer (2018)
    Liya Ding, Hye‐Jung Kim et al. Cell Reports
  45. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity (2017)
    Daniela Schmid, Chun Gwon Park et al. Nature Communications
  46. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection (2019)
    William Henry Hudson, Masao Hashimoto et al. Immunity
  47. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma (2017)
    Suzanne George, Diana Miao et al. Immunity
  48. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer (2015)
    Nicolás A. Giraldo, Étienne Becht et al. Clinical Cancer Research
  49. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells (2022)
    Ilaria Elia, Jared H. Rowe et al. Cell Metabolism
  50. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance (2023)
    Joon Seok Park, Francesca S. Gazzaniga et al. Nature
  51. The B7:CD28 family and friends: Unraveling coinhibitory interactions (2024)
    Kelly P. Burke, Apoorvi Chaudhri et al. Immunity

Immediate Impact

126 by Nobel laureates 62 from Science/Nature 282 standout
Sub-graph 1 of 17

Citing Papers

Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells
2020 StandoutScience
25 intermediate papers

Works of Gordon J. Freeman being referenced

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
2017 StandoutScience
Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production
2003 Standout
and 27 more

Author Peers

Author Last Decade Papers Cites
Gordon J. Freeman 53470 37868 14403 418 81.0k
Drew M. Pardoll 46168 44257 23146 398 81.6k
Robert D. Schreiber 47711 33142 20381 378 78.3k
Mark J. Smyth 52200 36937 19880 592 80.1k
Arlene H. Sharpe 47078 28206 16005 406 74.3k
Jedd D. Wolchok 29224 44357 15851 558 63.2k
James P. Allison 49382 38454 12845 480 70.9k
Lloyd J. Old 46929 33262 32823 714 84.6k
Tasuku Honjo 39003 22887 24577 579 71.1k
Wolf H. Fridman 30637 27029 16241 524 56.0k
Lieping Chen 35531 33760 9061 366 54.6k

All Works

Loading papers...

Rankless by CCL
2026